Skip to main content
Sign In

University of Colorado Denver

 

Jennifer M. Trujillo, PharmD, BCPS, CDE, BC-ADM

Associate Professor, Department of Clinical Pharmacy


Image of Jennifer Trujillo

Mailing address:

University of Colorado School of Pharmacy
Mail Stop C238
12850 E. Montview Blvd. V20-1222
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
First Floor
Room 1222

Contact:

Voice: 303-724-2624
Fax: 303-724-2637
E-Mail: Jennifer.Trujillo@ucdenver.edu

Training and Education:

Doctor of Pharmacy, University of Arizona (1997)
Pharmacy Practice Residency, Boston Medical Center, Boston, MA (1997-1998)
Board Certified Pharmacotherapy Specialist (1999, 2006)
American Association of Colleges of Pharmacy - Academic Leadership Fellows Program (2006-2007)

Clinical/Research Interests:

Dr. Trujillo practices at the The University of Colorado Center for Adult Diabetes Care and Research. The center's multidisciplinary team provides diabetes management and education to patients with both type 1 and type 2 diabetes. Clinical research areas of interest include inpatient and outpatient diabetes management and education. Dr. Trujillo also has a strong interest in the scholarship of teaching and learning, curricular development and assessment.

Teaching:

Dr. Trujillo co-directs the Patient-Centered Communication 1 and Pharmacotherapy 3 courses.  Content areas include patient-centered communication skills, health literacy, type 2 diabetes, and healthy eating.  

Recent Publications:

  • Anderson SM, Trujillo JM (corresponding).  Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2016;7(1):4-17.
  • Nuffer W, Trujillo JM.  Liraglutide: A New Option in the Treatment of Obesity.  Pharmacotherapy 2015;35(10):926-934. 
  • Hildreth KL, Van Pelt RE, Moreau KL, Grigsby J, Hoth KF, Pelak V, Anderson CA, Parnes B, Kittelson J, Wolfe P, Nakamura T, Linnebur SA, Trujillo JM, Aquilante CL, Schwartz RS. A randomized trial of pioglitazone or exercise in older adults with mild cognitive impairment. Dement Geriatr Cogn Disord Extra. 2015;5:51-63. 
  • Trujillo JM, Figler TA.  Teaching and Learning Health Literacy in a Doctor of Pharmacy Program. Am J Pharm Educ 2015;79(2):Article 27. 
  • Thompson, AM, Trujillo JM.  Dulaglutide:  The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes. Ann Pharmacother 2015;49(3):351-359. 
  • Trujillo JM, Nuffer W, Ellis SL.  GLP-1 Receptor Agonists: A Review of Head-to-Head Clinical Studies.  Ther Adv Endocrinol Metab 2015;6(1):19-28. 
  • Nuffer W, Trujillo JM, Ellis SL.  Technosphere Insulin (Afrezza): A new, inhaled prandial insulin.  Ann Pharmacother 2015;49(1):99-106.
  • Trujillo JM, Nuffer W.  GLP-1 Receptor Agonists for Type 2 Diabetes: Recent Developments and Emerging Agents. Pharmacotherapy 2014;34(11):1174-1186. 
  • Trujillo JM, Nuffer W.  Albiglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.  Ann Pharmacother 2014;48(11):1494-1501. 
  • Trujillo JM, Saseen JJ, Linnebur SA, Borgelt LM, Hemstreet B, Fish, DN. Impact of student-directed versus instructor-directed case discussions on student performance in a pharmacotherapy capstone course.  Am J Pharm Educ 2014;78(3):Article 56. 
  • King WM, McDermott MT, Trujillo JM (corresponding).  Initial Management of Severe Hyperglycemia in Patients with Type 2 Diabetes: An Observational Study.  Diabetes Ther 2013;4(2):375-384.  
  • Hume AL, Kirwin J, Bieber HL, Couchenour RL, Hall DL, Kennedy AK, LaPointe N, Burkhardt CD, Schilli K, Seaton T, Trujillo JM, Wiggins B.  Improving Care Transitions: Current Practice and Future Opportunities for Pharmacists.  Pharmacotherapy 2012;32(11):e326-e337. 
  • Trujillo JM.  Follow-up assessment of a faculty peer observation and evaluation program.  Am J Pharm Educ 2012;76(4):Article 61. 
  • Anderson SL, Trujillo JM, McDermott M, Saseen JJ. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc 2012;52:48-53. 
  • Anderson SL, Trujillo JM.  Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010;44:904-909.